Shares of BioNTech (BNTX) listed in the U.S. fell on Monday, as the company's weak forecast for the year overshadowed its better-than-expected quarterly performance.
BioNTech SE (NASDAQ:BNTX) will hold its Q4 2024 Earnings Conference Call on March 10, 2025, at 8:00 AM ET. The call will feature key company figures, including CEO Ugur Sahin and CFO Jens Holstein, along with various participants from financial institutions. Michael Horowicz, the Director of Investor Relations, will start the call.
A look ahead at the earnings reports of important companies that will be released next week and the key points to pay attention to.
On Tuesday, BioNTech announced in a regulatory document that the U.S. Food and Drug Administration has put a hold on a clinical trial for its malaria vaccine that is in the early to mid-stages.
The meeting of the Food and Drug Administration's vaccine advisory committee, which was meant to talk about the flu vaccine for the upcoming season, has been canceled. This is the second time a meeting with federal vaccine policy experts has been disrupted since Robert F. Kennedy Jr., a well-known vaccine skeptic, became the Health and Human Services secretary earlier this month.
Shares of MRNA, PFE, NVAX, and BNTX increased as people worried that a new virus in China might lead to another pandemic.
MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will release its financial results for the fourth quarter and the entire year of 2024 on Monday, March 10, 2025. On the same day, the Company will hold a conference call and webcast at 8:00 a.m. EDT (1:00 p.m. CET) for investors, financial analysts, and the public to discuss these results and share updates about the company.
BioNTech (BNTX) could see an increase in its stock price due to rising confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).
Stocks of vaccine companies dropped after a Senate committee decided to move forward with Robert F. Kennedy Jr.'s nomination to head the Department of Health and Human Services for a full vote.
MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) has announced that it has completed the acquisition of Biotheus, a biotechnology company focused on creating new antibodies for patients with cancer or inflammatory diseases. This acquisition, which was first revealed in November 2024, follows a successful partnership on the late-stage clinical product BNT327, a bispecific antibody aimed at PD-L1 and VEGF-A, along with other similar candidates.